GSK's (GSK) Buy Rating Reiterated at Shore Capital

Key Points

• Shore Capital has reiterated a "buy" rating for GSK, setting a price target of GBX 2,100, indicating a potential upside of 28.83% from its previous close.
• The stock currently has a consensus rating of "Hold" with a target price of GBX 1,637.50, as several analysts have mixed views including one buy and two hold ratings.
• Insider Wendy Becker purchased 526 shares at GBX 1,503 each, reflecting confidence in the company's performance as insiders have also bought a total of 576 shares valued at approximately $865,799 over the last quarter.

GSK (LON:GSK - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at Shore Capital in a report released on Monday,Digital Look reports. They presently have a GBX 2,100 price objective on the stock. Shore Capital's price target points to a potential upside of 28.83% from the company's previous close.

GSK has been the topic of several other reports. Berenberg Bank reissued a "hold" rating and set a GBX 1,600 price target on shares of GSK in a research report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a GBX 1,450 target price on shares of GSK in a report on Thursday, July 31st. Finally, JPMorgan Chase & Co. reaffirmed an "under review" rating on shares of GSK in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, GSK presently has a consensus rating of "Hold" and a consensus target price of GBX 1,637.50.

GSK Stock Performance

LON:GSK opened at GBX 1,630 on Monday. GSK has a 1 year low of GBX 1,242.50 and a 1 year high of GBX 1,684.50. The firm has a 50 day moving average of GBX 1,512.36 and a 200-day moving average of GBX 1,444.63. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The stock has a market capitalization of £65.60 billion, a P/E ratio of 19.71, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, sell-side analysts anticipate that GSK will post 175.980975 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Wendy Becker purchased 526 shares of the stock in a transaction on Friday, September 19th. The shares were purchased at an average cost of GBX 1,503 per share, with a total value of £7,905.78. Over the last quarter, insiders have bought 576 shares of company stock valued at $865,799. 0.20% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.